Journal of Cancer Research and Therapeutics Close
 

Figure 3: Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio were compared with tumor–node–metastasis and independent tumor–node–metastasis stages in patients with non-small cell lung cancer. Significant associations were identified between tumor–node–metastasis stage and neutrophil-to-lymphocyte ratio level (a) (P = 0.037), and between tumor–node–metastasis stage and platelet-to-lymphocyte ratio level (b) (P = 0.001). An increased neutrophil-to-lymphocyte ratio was intrinsically associated with T stage (c) and N stage (e) (all P < 0.05). (d) Significant difference was observed between T stage and platelet-to-lymphocyte ratio (P = 0.028). There was no differences were between M stages and neutrophil-to-lymphocyte ratio levels (g), or between N stage and platelet-to-lymphocyte ratio (f), or between M stage and platelet-to-lymphocyte ratio (h) (all P > 0.05)

Figure 3: Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio were compared with tumor–node–metastasis and independent tumor–node–metastasis stages in patients with non-small cell lung cancer. Significant associations were identified between tumor–node–metastasis stage and neutrophil-to-lymphocyte ratio level (a) (<i>P</i> = 0.037), and between tumor–node–metastasis stage and platelet-to-lymphocyte ratio level (b) (<i>P</i> = 0.001). An increased neutrophil-to-lymphocyte ratio was intrinsically associated with T stage (c) and N stage (e) (all <i>P</i> < 0.05). (d) Significant difference was observed between T stage and platelet-to-lymphocyte ratio (<i>P</i> = 0.028). There was no differences were between M stages and neutrophil-to-lymphocyte ratio levels (g), or between N stage and platelet-to-lymphocyte ratio (f), or between M stage and platelet-to-lymphocyte ratio (h) (all <i>P</i> > 0.05)